GSK told to pay higher royalties to AZ on Zejula sales

[cafead]

via A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibitor Lynparza.

article source